The total return over the past 12 months is +132.62% vs. +16.94% for the S&P 500. So far it's up +302.92% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +132.62% | +46.07% | (3.57%) | N/A | N/A | N/A |
| Total Return CAGR | +132.62% | +46.07% | (3.57%) | N/A | N/A | N/A |
| Revenue CAGR | +101.28% | +10.42% | (31.78%) | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
AbCellera Biologics Inc. (ABCL)
| Year | Start price | End price | ABCL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.42 | $13.78 | +302.92% | +14.51% | +288.41% |
| 2025 | $2.93 | $3.42 | +16.72% | +17.72% | (1.00%) |
| 2024 | $5.71 | $2.93 | (48.69%) | +24.89% | (73.58%) |
| 2023 | $10.13 | $5.71 | (43.63%) | +26.19% | (69.82%) |
| 2022 | $14.30 | $10.13 | (29.16%) | (18.17%) | (10.99%) |
| 2021 | $40.24 | $14.30 | (64.46%) | +28.74% | (93.20%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
